Home Menu

Site Navigation



Parkinson's Disease Tulip


advertisement
NeuroTalk Support Groups > > >

IPX066 news

Reply
 
Thread Tools Display Modes
Old 10-12-2012, 08:12 AM #1
soccertese soccertese is offline
Magnate
  
Join Date: Nov 2007
Posts: 2,531
15 yr Member
soccertese soccertese is offline
Magnate
 
Join Date: Nov 2007
Posts: 2,531
15 yr Member
Default IPX066 news
Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date to January 21, 2013

http://finance.yahoo.com/news/impax-...120000996.html
soccertese is offline   Reply With QuoteReply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
IPX066 Open Label Extension Study illbethere Parkinson's Disease Clinical Trials 21 08-18-2011 09:52 AM
IPX066, Phase III results CarolynS Parkinson's Disease Clinical Trials 0 03-15-2011 05:39 AM
APEX-PD Phase III Trial of IPX066 in Parkinson's Disease, older news soccertese Parkinson's Disease 1 08-03-2010 10:32 AM
IPX066 for PD: who has the lastest? tracy chen Parkinson's Disease 0 07-15-2009 06:54 PM
Impax Pharmaceuticals: Phase III trial of IPX066 in Parkinson’s Disease Stitcher Parkinson's Disease Clinical Trials 0 04-20-2009 10:10 AM


All times are GMT -5. The time now is 04:49 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home